El interés en corto de Maravai LifeSciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Maravai LifeSciences. Los datos de interés en corto se actualizan cada dos semanas.

Maravai LifeSciences (NASDAQ:MRVI) Bolsa, Informe de interés en corto

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

Cloudflare (NET) is currently navigating the 7th Phase of its 18-Phase Adhishthana Cycle. While the structure remains constructive, investors expecting a breakout may need to exercise patience as the real move may not unfold until March 2026. Here's a detailed look at why.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="675" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana-.png" alt="Fig.1 Cloudflare's Adhishthana Phases (Source: Adhishthana.com)" class="wp-image-13784" style="width:679px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana--300x169.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana--1024x576.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana--768x432.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /></figure>
<h3 class="wp-block-heading">How Has Cloudflare Aligned With the Adhishthana Principles So Far?</h3>
On the weekly chart, Cloudflare has displayed a strong 94% alignment with the Adhishthana Principles, our proprietary cyclical framework that combines quantitative signals with behavioral archetypes. Here are some key highlights from past phases of the current cycle:
<h4 class="wp-block-heading">Phase 2: The Rally of Buddhi</h4>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1098" height="1000" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana-.png" alt="Fig.2 Cloudflare Stock Phase 2 (Source: Adhishthana.com)" class="wp-image-13777" style="width:486px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana-.png 1098w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana--300x273.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana--1024x933.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana--768x699.png 768w" sizes="(max-width: 1098px) 100vw, 1098px" /><figcaption class="wp-element-caption">Fig.2 Cloudflare Stock Phase 2 (Source: Adhishthana.com)</figcaption></figure>
Cloudflare traded in a tight consolidation for exactly 37 bars, in line with what the framework prescribes. Following that, it broke out and rallied by ~216%, marking a textbook Rally of Buddhi.
<h4 class="wp-block-heading">Phase 3: Yajya Formation</h4>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="686" height="636" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104235/Cloudfare-Phase-3-Adhishthana-.png" alt="Fig.3 Cloudflare Stock Phase 3(Source: Adhishthana.com)" class="wp-image-13778" style="width:471px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104235/Cloudfare-Phase-3-Adhishthana-.png 686w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104235/Cloudfare-Phase-3-Adhishthana--300x278.png 300w" sizes="(max-width: 686px) 100vw, 686px" /><figcaption class="wp-element-caption">Fig.3 Cloudflare Stock Phase 3 (Source: Adhishthana.com)</figcaption></figure>
During Phase 3, Cloudflare formed a classic Yajya Formation, a distinctive Adhishthana hand-arc structure. It rallied slightly, formed a smooth arc, and then corrected sharply, completing the behavioral cycle of this phase precisely.
<h4 class="wp-block-heading">Phase 6: Discovery of Nirvana</h4>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1014" height="710" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104258/Cloudfare-Phase-6-Adhishthana.png" alt="Fig.4 Cloudflare Stock Phase 6 (Source: Adhishthana.com)" class="wp-image-13779" style="width:554px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104258/Cloudfare-Phase-6-Adhishthana.png 1014w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104258/Cloudfare-Phase-6-Adhishthana-300x210.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104258/Cloudfare-Phase-6-Adhishthana-768x538.png 768w" sizes="(max-width: 1014px) 100vw, 1014px" /><figcaption class="wp-element-caption">Fig.4 Cloudflare Stock Phase 6 (Source: Adhishthana.com)</figcaption></figure>
After 24 bars of trading in Phase 6, Cloudflare formed its Level of Nirvana at $85.13. This level now acts as both a valuation barometer and a potential price magnet during corrections throughout the cycle.
<h3 class="wp-block-heading">What's Unfolding in Cloudflare&#8217;s 7th Phase?</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="910" height="608" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104354/Cloudfare-Phase-7.png" alt="Fig.5 Cloudflare Stock Phase 7 (Source: Adhishthana.com)" class="wp-image-13780" style="width:537px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104354/Cloudfare-Phase-7.png 910w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104354/Cloudfare-Phase-7-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104354/Cloudfare-Phase-7-768x513.png 768w" sizes="(max-width: 910px) 100vw, 910px" /><figcaption class="wp-element-caption">Fig.5 Cloudflare Stock Phase 7 (Source: Adhishthana.com)</figcaption></figure>
Phase 7 brought the expected &#8220;Fall of Artha and Artharthi&#8221;, a behavioral correction designed to flush out speculative hands and reset the valuation. Cloudflare dropped nearly 48% shortly after entering the phase, accompanied by exactly seven red bars, which is highly consistent with Adhishthana principles.
Interestingly, the correction found support just above the Nirvana level at $85.13. Since then, the stock has rebounded strongly, nearly reclaiming the Phase 7 entry high around $177.37. However, a decisive breakout above this level may remain elusive for now.
<h3 class="wp-block-heading">Why Cloudflare&#8217;s Breakout Might Be Delayed</h3>
While momentum has returned, Cloudflare remains in Phase 7, which is not typically when major breakouts occur. According to Adhishthana Principles, the supreme move is expected during Phase 9, set to begin on 2 March 2026.
Until then, the stock may continue to form what we call the Cakra, or &#8220;Arc&#8221;, a bullish rising channel with a curve. The true breakout is more likely to occur after the completion of this structure, when Phase 9 begins.
<h3 class="wp-block-heading">Investor Takeaway</h3>
Cloudflare is building a constructive base within its Phase 7 structure, and its adherence to Adhishthana Cyclical Principles has been striking. For long-term investors:
<ul class="wp-block-list">
<li>Accumulation near or just above the Nirvana level ($85.13) could be prudent for those seeking deep-cycle opportunities. </li>
<li>Chasing strength near current highs may not be optimal, as a decisive breakout is not expected before Phase 9 begins in March 2026. </li>
<li>Watch the Cakra closely; if the bullish arc remains intact, the setup continues to improve. However, if the Cakra breaks to the downside, it could attract significant selling pressure.</li>
</ul>
The stock remains a buy-on-dip candidate, with a stronger case for a breakout emerging in its Phase 9.&nbsp;

Equities

Technicals

Opinion

Signals

Trading Ideas

Cloudflare Strengthening, Yet Breakout Unlikely Until 2026

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.73%</li>
<li>Barclays analyst Gaurav Jain maintained an Underweight rating and raised the price target from $46 to $49 on May 2, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Matthew Smith maintained a Buy rating and raised the price target from $60 to $63 on April 30, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On April 29, Altria Group posted upbeat quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MO <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603"><img loading="lazy" decoding="async" width="912" height="858" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074100/image-26.png" alt="" class="wp-image-936503" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074100/image-26.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074100/image-26-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074100/image-26-768x723.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.15%</li>
<li>Wells Fargo analyst Chris Carey maintained an Equal-Weight rating and cut the price target from $27 to $23 on June 2, 2025. This analyst has an accuracy rate of 63%.</li>
<li>JP Morgan analyst Ken Goldman maintained a Neutral rating and cut the price target from $26 to $25 on May 6, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: On May 1, Hometown Food Company announced plans to acquire Chef Boyardee Brand from Conagra Brands for $600 million.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest CAG <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603"><img loading="lazy" decoding="async" width="922" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074137/image-27.png" alt="" class="wp-image-936504" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074137/image-27.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074137/image-27-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074137/image-27-768x708.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.80%</li>
<li>Guggenheim analyst Robert Drbul maintained a Buy rating and cut the price target from $155 to $115 on May 27, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Telsey Advisory Group analyst Joseph Feldman downgraded the stock from Outperform to Market Perform and cut the price target from $130 to $110 on May 22, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 21, Target registered adjusted earnings per share of $1.30, missing analysts' consensus estimate of $1.64. Quarterly sales of $23.85 billion (down 2.8% year over year) missed the Street view of $24.32 billion.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest TGT <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603"><img loading="lazy" decoding="async" width="926" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074751/image-28.png" alt="" class="wp-image-936511" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074751/image-28.png 926w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074751/image-28-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074751/image-28-768x703.png 768w" sizes="(max-width: 926px) 100vw, 926px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Wall Street's Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields

JP Morgan analyst Doug Anmuth upgrades Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) from Neutral to Overweight and raises the price target from $35 to $40.

Upgrades

PINS

JP Morgan Upgrades Pinterest to Overweight, Raises Price Target to $40

The Ethereum Foundation, a key supporter of Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), laid off research and development staff on Monday as <a href="https://www.benzinga.com/markets/25/04/45047461/i-dont-think-ethereum-will-survive-more-than-10-to-15-years-cardano-founder-charles-hoskinson-says">part of a strategic restructuring</a>.
What Happened: The Switzerland-based nonprofit announced it is rebranding its Protocol Research and Development division as &#8220;Protocol&#8221; with three core priorities: scaling Ethereum&#8217;s base layer, expanding blobspace for data availability, and improving user experience. 
The foundation did not disclose the number of affected employees, stating only that &#8220;some members of PR&amp;D won&#8217;t be continuing with the Ethereum Foundation.&#8221;
Co-executive director Hsiao-Wei Wang said on X the restructuring aims to &#8220;empower our internal teams to focus more clearly and drive key initiatives forward.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Ethereum Foundation&#39;s R&amp;D team structure update: We&#39;re hopeful that this new structure will empower our internal teams to focus more clearly and drive key initiatives forward. Today, we also had to make some incredibly difficult decisions. Saying goodbye to talented and… <a href="https://t.co/DJHqSMt4R2">https://t.co/DJHqSMt4R2</a>
&mdash; hww.eth &#x7C; Hsiao-Wei Wang (@hwwonx) <a href="https://twitter.com/hwwonx/status/1929629853629948286?ref_src=twsrc%5Etfw">June 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45741617/chinas-manufacturing-activity-crashes-to-2022-lows-in-may-amid-trump-tariff-woes">China&#8217;s Manufacturing Activity Crashes To 2022 Lows In May Amid Trump Tariff Woes</a>
Why It Matters: The restructuring follows governance changes <a href="https://www.benzinga.com/markets/25/05/45173642/vc-says-this-may-be-the-beginning-of-the-eth-revival-as-the-ethereum-foundation-formalizes-structura">that began in 2024</a>. The foundation faced criticism over spending, personnel policies, and conflicts of interest after researchers accepted paid advisory roles at competing protocols.
The leadership shake-up began in February when Executive Director Aya Miyaguchi <a href="https://www.benzinga.com/content/43960855/aya-miyaguchi-becomes-president-as-ethereum-foundation-reshapes-leadership">transitioned to president</a>, following death threats and harassment over her management. Ethereum co-founder Vitalik Buterin has asserted control over foundation decisions while rejecting community demands for further leadership changes.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We are indeed currently in the process of large changes to EF leadership structure, which has been ongoing for close to a year. Some of this has already been executed on and made public, and some is still in progress. What we&#39;re trying to achieve is primarily the following…
&mdash; vitalik.eth (@VitalikButerin) <a href="https://twitter.com/VitalikButerin/status/1880635379771904423?ref_src=twsrc%5Etfw">January 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45741571/elon-musk-weighs-in-on-how-much-power-humanoid-robots-would-require-amid-teslas-optimus-push">Elon Musk Weighs In On How Much Power Humanoid Robots Would Require Amid Tesla&#8217;s Optimus Push</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

Ethereum Foundation Lays Off R&D Staff, Rebrands Division To Focus On Scaling, Data Availability And User Experience

RBC Capital analyst Brad Erickson initiates coverage on Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Sector Perform rating and announces Price Target of $125.

Initiation

RDDT

RBC Capital Initiates Coverage On Reddit with Sector Perform Rating, Announces Price Target of $125

Jefferies analyst Flora Bocahut upgrades UBS Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) from Hold to Buy.

Jefferies Upgrades UBS Gr to Buy

<ul>
<li>Enlight expands its successful Gecama Wind Project, transforming it into the largest hybrid power complex of its kind in Spain</li>
<li>The project combines wind, solar, and utility-scale battery storage to deliver clean electricity around the clock</li>
<li>The hybrid project, with a total capacity of 554 MW and 220 MWh, is expected to generate approximately $100 million in annual revenue</li>
<li>The project, among the first in Spain to incorporate a utility-scale battery energy storage system, is expected to enhance grid stability following extended blackouts recently experienced in the country</li>
</ul>
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Enlight Renewable Energy ("Enlight", ", the Company", NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLT#NASDAQ">ENLT</a>, TASE: ENLT.TA), a leading renewable energy platform, today announced the signing of financing agreements totaling approximately $310 million for the Hybridisation of the Gecama Project in Spain. As part of the project, Enlight will integrate a solar array and utility-scale energy storage system at its operational Gecama facility. Gecama is currently the country's largest wind farm, with a capacity of 329 MW.
The integrated facility, with a total capacity of 554 MW and 220 MWh, will deliver clean electricity around the clock at a competitive cost of generation, yielding high returns. This performance is made possible by combining technologies with complementary generation profiles throughout most of the day, alongside a battery system that enables optimized use of energy resources.
Once completed, the Gecama Hybrid Project is expected to become the largest renewable energy complex of its kind in Spain and to play a key role in advancing storage infrastructure in line with the Spanish national plan to combat climate change and enhance energy supply stability. The need for such energy storage systems is particularly pressing considering the widespread blackouts Spain experienced in April 2025.
Subject to the completion of final development milestones, the solar and storage components of the Hybrid Project are expected to reach commercial operation (COD) in the second half of 2026. Their addition is expected to increase the Gecama Project's annual revenues by $38–40 million and EBITDA by $31–33 million in the first full year of operation. With all three components in full operation, the integrated project is expected to generate annual revenues of $95–105 million and EBITDA of $75–80 million.
The financing transaction of approximately $310 million includes two tranches: covering the refinancing of the Gecama Wind Project and financing for the construction of the Hybrid Project. Both tranches bear a fixed interest rate of ~5.1% and will be fully amortizing by 2045 and 2046, respectively.
After repaying the existing debt and funding necessary reserves and transaction costs, over $150 million of the secured debt will be allocated to the construction of the Hybrid Project, with a total estimated cost of $195–205 million, while the remaining balance will be funded through equity.

ENLT

Enlight Renewable Energy Signs Financing Agreements Totaling About $310M For Hybridisation Of Gecama Project In Spain

Jefferies analyst Chris LaFemina downgrades Rio Tinto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) from Buy to Hold.

Downgrades

Jefferies Downgrades Rio Tinto to Hold

Redburn Atlantic analyst Sam Hudson upgrades Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) from Sell to Neutral and raises the price target from $28 to $45.

Redburn Atlantic Upgrades Advance Auto Parts to Neutral, Raises Price Target to $45

<ul>
<li>Record May ADV in interest rate, metals and cryptocurrency products</li>
<li>SOFR futures ADV grew 31% over May 2024</li>
<li>International ADV increased 15% to 8.7 million contracts</li>
</ul>
CHICAGO, June 3, 2025 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today reported it reached the highest May average daily volume (ADV) on record at 28.9&nbsp;million contracts, an increase of&nbsp;11% year-over-year. Market statistics are available in greater detail at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=1663060920&amp;u=https%3A%2F%2Fcmegroupinc.gcs-web.com%2Fmonthly-volume&amp;a=https%3A%2F%2Fcmegroupinc.gcs-web.com%2Fmonthly-volume">https://cmegroupinc.gcs-web.com/monthly-volume</a>.
May&nbsp;2025 ADV across asset classes includes:
<ul>
<li>Record May <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=2648253738&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Finterest-rates.html%3Fredirect%3D%2Ftrading%2Finterest-rates%2F&amp;a=Interest+Rate">Interest Rate</a> ADV of 16.2 million contracts</li>
<li><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=1996164365&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fequities.html%3Fredirect%3D%2Ftrading%2Fequity-index%2F&amp;a=Equity+Index">Equity Index</a> ADV of 6.6 million contracts</li>
<li><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=2442821376&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fenergy.html%3Fredirect%3D%2Ftrading%2Fenergy%2F&amp;a=Energy">Energy</a> ADV of 2.6 million contracts</li>
<li><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=2478824282&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fagriculture.html%3Fredirect%3D%2Ftrading%2Fagricultural%2F&amp;a=Agricultural">Agricultural</a> ADV of 1.6 million contracts</li>
<li>Record May <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=1563010986&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fmetals.html%3Fredirect%3D%2Ftrading%2Fmetals%2F&amp;a=Metals">Metals</a> ADV of 933,000 contracts</li>
<li><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=3967813048&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Ffx.html%3Fredirect%3D%2Ftrading%2Ffx%2F&amp;a=Foreign+Exchange">Foreign Exchange</a> ADV of 893,000 contracts</li>
<li>Record May <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440936-1&amp;h=2370709692&amp;u=https%3A%2F%2Fwww.cmegroup.com%2Fmarkets%2Fcryptocurrencies.html&amp;a=Cryptocurrency">Cryptocurrency</a> ADV of 197,000 contracts ($10 billion notional)</li>
</ul>
Additional May 2025 product highlights compared to May 2024:
<ul>
<li>Interest Rate ADV increased 13%
<ul>
<li>SOFR futures ADV increased 31% to 4 million contracts</li>
<li>U.S. Treasury futures and options&nbsp;ADV increased 6% to 10.6 million contracts</li>
<li>Interest Rate options&nbsp;ADV increased 11% to 2.7 million contracts</li>
</ul>
</li>
<li>Equity Index ADV increased 15%
<ul>
<li>Micro&nbsp;E-mini Nasdaq 100 futures ADV increased 37% to 1.5 million contracts</li>
<li>Micro&nbsp;E-mini S&amp;P 500 futures ADV increased 60% to 1.3 million contracts</li>
</ul>
</li>
<li>Energy ADV increased 6%
<ul>
<li>Record May Energy options&nbsp;ADV of 445,000 contracts</li>
</ul>
</li>
<li>Metals ADV increased 8%
<ul>
<li>Record monthly Micro Gold futures&nbsp;ADV of 347,000 contracts</li>
</ul>
</li>
<li>Cryptocurrency ADV increased 145%
<ul>
<li>Record monthly Ether futures&nbsp;ADV of 17,000 contracts</li>
<li>Micro Ether futures&nbsp;ADV increased 235% to 92,000 contracts</li>
<li>Micro&nbsp;Bitcoin futures ADV increased 95% to 65,000 contracts</li>
</ul>
</li>
<li>Micro Products ADV
<ul>
<li>Micro&nbsp;E-mini Equity Index futures and options ADV of 3 million contracts represented 45.3% of overall Equity Index ADV and Micro WTI Crude Oil futures accounted for 2.5% of overall Energy ADV</li>
</ul>
</li>
<li>International ADV increased 15% to 8.7 million contracts, with EMEA ADV up 14% to 6.4 million contracts and Asia ADV up 24% to 2 million contracts</li>
<li>BrokerTec U.S. Repo average daily notional value (ADNV) increased 28.6% to $352 billion, European Repo ADNV increased 3% to €306.7 billion and U.S. Treasury ADNV increased 20% to $101.1 billion</li>
<li>EBS Spot FX ADNV increased 27% to $67.8 billion and FX Link ADV increased 52% to 43,000 contracts ($2.9 billion notional per leg)</li>
<li>Customer average collateral balances to meet performance bond requirements for rolling 3-months ending April 2025 were $97.2 billion for cash collateral and $162.9 billion for non-cash collateral</li>
</ul>

CME Group May Average Daily Volume Up 11% To 28.9 Mln Contracts From Last Year

As &#8220;Trump Always Chickens Out&#8221; or TACO trade was trending last week, the &#8220;Anywhere But The USA&#8221; or ABUSA trade is also emerging as a notable market trend in 2025, driven by concerns over U.S. economic policies, trade uncertainties, and a global shift toward diversified investment strategies.
What Happened: While the TACO trade signals a widespread belief that Donald Trump&#8216;s possible tariff rollbacks or extensions could be opportunities to buy the dip, the new &#8220;Anywhere But The USA&#8221; or ABUSA trade suggests fleeing the U.S. assets amid uncertainties and chaotic policy changes.
According to a 2024 <a href="https://carnegieendowment.org/research/2024/05/time-to-reset-the-us-trade-agenda?lang=en">report</a> by Carnegie Endowment for International Peace, former U.S. Trade Representative Robert Lighthizer, the architect of Trump's 2017-2021 trade policy, advocated for tariffs to protect U.S. industries and pressure other countries to cease unfair trade practices.
However, experts cited in the report warn that such policies could isolate the U.S. economically, driving investors to look elsewhere, aligning with the ABUSA narrative.
Meanwhile, Alan Siow, the investment manager at Ninety One, <a href="https://www.cnbc.com/2025/06/02/inside-the-abusa-trade-anywhere-but-the-usa.html">told</a> CNBC that ABUSA trade is a &#8220;recalibration toward global balance, cyclical recovery, and multi-polar growth&#8221; rather than a contrarian move
He argues that the trade reflects a decade-long shift away from a &#8220;widespread preference for U.S.&#8221; assets, driven by seesawing trade policies, proposed foreign capital taxes, and concerns over U.S. fiscal spending.
Siow's perspective emphasizes a structural change in investor behavior, where the U.S. is no longer the default safe haven.
He sees ABUSA as a logical response to a U.S. economic environment perceived as increasingly risky due to policy flip-flops, such as Trump's tariff threats and retreats, linked to the TACO trade, and a dollar selloff that has made non-U.S. markets more attractive. While these strategies promote the &#8220;Sell America&#8221; narrative, an LPL Financial note added that fear of asset sales from the &#8220;de-dollarization&#8221; and &#8220;Sell America&#8221; is also a potential headwind to Treasury yields.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45739065/sp-500-reverses-short-term-downtrend-after-april-lows-technical-evidence-shows-recovery-is-real-and-not-a-bull-trap-or-bear-market-rally">S&amp;P 500 Reverses Short-Term Downtrend After April Lows: Technical Evidence Shows &#8216;Recovery Is Real&#8217; And Not A &#8216;Bull Trap&#8217; Or &#8216;Bear Market Rally&#8217;</a>
Why It Matters: Rami Cassis, the founder of London's Parabellum, also added another perspective to the rise in ABUSA trade, describing the reaction of investors toward the U.S. as &#8220;emotive.&#8221;
According to Cassis, beyond his unpredictable trade policies, a number of other contentious stances held by Trump, including his approach to the conflict in Ukraine and his position on LGBTQIA+ rights, also played a role in discouraging some individuals from investing in America.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Tuesday. The SPY was down 0.38% at $590.45, while the QQQ declined 0.36% to $521.32, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/treasuries/25/06/45739830/us-dollar-decouples-with-10-year-treasuries-as-trade-tensions-change-long-standing-relationships-between-asset-classes">US Dollar Decouples With 10-Year Treasuries As Trade Tensions Change Long-Standing Relationships Between Asset Classes </a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

TACO Trade To 'Anywhere But The USA': Viral Trends Echo 'Sell America' Amid Tumultuous Federal Policies

US drug giant Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a bid exceeding $3 billion.
While MoonLake turned down the initial offer, talks may be revived.
The potential deal signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cancer drug Keytruda</a> faces patent expiration as early as 2028.
MoonLake Immunotherapeutics&#8217; lead development asset sonelokimab is a novel investigational Nanobody&nbsp;for inflammatory diseases.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/05/45701905/merck-kandlelit-trials-spark-hope-lung-cancer-trials" target="_blank" rel="noreferrer noopener">Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers</a>
Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.
Merck is also grappling with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million" rel="noreferrer noopener">falling sales of its Gardasil</a> vaccine in China and underwhelming uptake of its new hypertension drug, Winrevair.
Per a Financial Times <a target="_blank" href="https://www.ft.com/content/5899ea69-e5fe-49f1-8ada-79f26c9254d8" rel="noreferrer noopener">report</a> on Monday, Merck made a nonbinding offer earlier this year, valuing MoonLake above its $2.6 billion market capitalization.
Founded in 2021 by former McKinsey partner Jorge Santos da Silva, MoonLake has garnered investor interest, with its stock price climbing nearly 50% over the past two years.
The FT report added that the company hired Goldman Sachs and Morgan Stanley to advise on the sale process.
Over the past year, Merck shares have dropped 39%, significantly underperforming the broader S&amp;P 500 pharmaceutical index, which declined by 11%.
In April, MoonLake Immunotherapeutics entered into an agreement with Hercules Capital, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NASDAQ">HTGC</a>) for up to $500 million in non-dilutive capital, of which $75 million will be drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44624282/moonlake-secures-up-to-500-million-in-non-dilutive-financing-from-hercules-capital-and-announces-a" rel="noreferrer noopener">strategy and funding needs</a>.
In January, MoonLake announced that patients have been screened in three new trials across three new indications <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42869804/moonlake-initiates-three-new-clinical-trials-and-further-expands-the-portfolio-of-indications-for-" rel="noreferrer noopener">to evaluate sonelokimab</a>.
The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA), as well as adult patients with HS and active psoriatic arthritis (PsA).
This increases the number of clinical trials led by MoonLake to ten and aligns with the company&#8217;s plan to enroll over 3,000 patients in clinical trials with sonelokimab since its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45358838/moonlake-immunotherapeutics-reports-first-quarter-2025-financial-results-and-provides-a-business-u" rel="noreferrer noopener">founding in 2021</a>.
Price Action: MLTX stock is trading higher by 21.1% to $49.84 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45731052/warner-bros-debt-downgrade-is-an-ironically-positive-event-analyst" target="_blank" rel="noreferrer noopener">Warner Bros&#8217; Debt Downgrade Is An &#8216;Ironically Positive&#8217; Event: Analyst</a></li>
</ul>
Photo by tada images via Shutterstock

Biotech

Health Care

Rumors

Movers

General

HTGC

MLTX

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and raises the price target from $9 to $11.

TSHA

Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Raises Price Target to $11

Energys Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) ("Energys Group" or the "Company", together with its subsidiaries, the "Group"), a vertically integrated energy efficiency and decarbonisation solutions provider for the built environment, is pleased to announce the award of the second tranche of LED lighting projects from Ark Multi-Academy Trust ("Ark"), an education charity based in London, United Kingdom.
The LED lighting projects involve upgrading existing infrastructure with the latest generation of LED lighting systems and intelligent controls. Upon completion, the projects are expected to deliver annual savings of approximately £1.4 million and reduce carbon emissions by over 900 tonnes annually. To date, the Company has completed Phase I of the projects, valued at £1.2 million. Riding on the successful completion and its proven track record, the Company has secured an additional&nbsp;£1.1 million in contracts which will commence immediately, along with £1.2 million for works scheduled for August 2025. A further £2.0 million later in 2025 is anticipated to finalise the programme, bringing the total value of works to £5.5 million.

ENGS

Energys Group Awarded Second Tranche Of LED Lighting Projects From Ark Multi-Academy Trust

RVSN

Rail Vision Lands $335K Follow-Up Order From Top Latin American Miner

Guidance

OLLI

Ollie's Bargain Outlet Affirms FY2025 Adj EPS Guidance of $3.65-$3.75 vs $3.73 Est; Raises FY2025 Sales Guidance from $2.56B-$2.59B to $2.58B-$2.60B vs $2.58B Est

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $34 to $11.

RCKT

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11

TSLA reverses early down move after signal from TradePulse
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/02212102/Screenshot-2025-06-02-at-5.18.27%E2%80%AFPM-1-1024x1009.png" alt="" class="wp-image-13760" /></figure>
Tesla lnc. (TSLA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 11:00 AM on June 2nd, a significant trading signal occurred for Tesla Inc., (TSLA) as it demonstrated a Power Inflow at a price of $337.32. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Tesla's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Tesla's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TSLA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025</a> which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $337.32. The returns on the High price ($342.75) and Close price ($342.69) after the Power Inflow are respectively 1.6% and 1.59%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.They were close today but is not always the case
Results are not indicative of future results

TSLA

Tesla Rises 1.6% After Power Inflow Signal

- Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine ("DMT") and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 -
- Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54264056&amp;newsitemid=20250603724552&amp;lan=en-US&amp;anchor=Cybin&amp;index=1&amp;md5=9893a04fd89d51c1e361a5d6057c93f2">Cybin</a> Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder ("GAD").
The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ("IM") injection, including CYB004.

CYBN

Cybin Granted U.S. Patent For CYB004 Deuterated DMT In Development For Treatment Of Generalized Anxiety Disorder

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and lowers the price target from $74 to $54.

NTLA

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $54

Legal

Press Releases

MRVI DEADLINE TODAY: Maravai LifeSciences (MRVI) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI

Penny Stocks

Small Cap

MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Investors who lost money on Maravai LifeSciences Holdings, Inc.(MRVI) should contact Levi & Korsinsky about pending Class Action - MRVI

Earnings

Maravai Lifesciences Reports First Quarter 2025 Financial Results

TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines

TriLink BioTechnologies® debuts its first mRNA synthesis kit with CleanCap® capping technology; Celebrates launch with kit donations to top academic institutions

Maravai LifeSciencesReleases 2024 Sustainability Report

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

MRVI

AbCellera Biologics

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Maravai LifeSciences

Interés en corto

Maravai LifeSciences (NASDAQ:MRVI) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL